Press release
Bispecific Antibody Market with Insights from Immunomedics, Genmab, OncoMed pharma-healthcare, EMD Serono, Merus, Pieris, MacroGenics, Emergent BioSolutions
Bispecific Antibody Market
You can access a sample PDF report here: https://www.statsndata.org/download-sample.php?id=162587
Recent advancements are driving the growth of the bispecific antibody market. Technological breakthroughs in biotechnology, particularly in the realms of drug development and clinical trials, have led to an influx of new therapies. Strategic partnerships among biopharmaceutical companies are fostering collaborative research and development efforts, enhancing the pace of innovation. These collaborations often focus on optimizing the structure and functionality of bispecific antibodies, thus improving patient outcomes. For executives and investors, the bispecific antibody market presents actionable insights into the future of therapeutic antibodies, highlighting the importance of staying ahead of the curve in a rapidly evolving landscape.
Key Growth Drivers and Trends
Several key growth drivers are shaping the bispecific antibody market. Sustainability is becoming a central concern for the industry, with companies adopting greener practices in manufacturing and development. The digitization of healthcare is also playing a crucial role, as advanced data analytics and electronic health records facilitate personalized medicine approaches. As patients and healthcare providers increasingly seek targeted therapy options, the demand for bispecific antibodies continues to rise.
Transformative trends are further propelling market growth. The integration of artificial intelligence into drug development is streamlining processes, from initial design to clinical trial management. Product customization is becoming more prevalent, allowing for therapies tailored to individual patient profiles. Emerging technologies, such as digital twins and virtual reality, are also enhancing the research and development landscape in biotechnology. These innovations are not only improving the efficacy and safety of bispecific antibodies but also reducing the time and cost associated with bringing new therapies to market.
Market Segmentation
The bispecific antibody market can be segmented based on type and application, providing a clearer understanding of its diverse landscape.
Segment by Type:
- Monoclonal Antibodies (Mab) or Peptide
- Bispecific T-cell Engagers (BiTE)
- Bispecific Monoclonal Antibodies (mAb)
- Chimeric Antigen Receptor T-cell (CAR-T)
- Antibody-Drug Conjugates (ADC)
- Small Molecules
Segment by Application:
- Oncology
- Solid Tumors
- Inflammation
- Cardiovascular
- General Medicine
This segmentation reveals the multifaceted nature of bispecific antibodies, catering to various therapeutic needs. The oncology segment, particularly, is experiencing robust growth as bispecific antibodies demonstrate significant potential in treating solid tumors and hematological malignancies.
Get 30% Discount On Full Report: https://www.statsndata.org/ask-for-discount.php?id=162587
Competitive Landscape
The bispecific antibody market is characterized by a competitive landscape featuring several prominent players. Here are some of the leading companies making strides in this space:
- Immunomedics: Known for its pioneering work in antibody-drug conjugates, Immunomedics has recently expanded its portfolio to include bispecific antibodies, focusing on innovative cancer therapies.
- Genmab: This company has been at the forefront of bispecific antibody technology, with several collaborations aimed at developing next-generation immunotherapies for oncology.
- OncoMed Pharmaceuticals: With a strong emphasis on cancer treatment, OncoMed is actively pursuing bispecific antibody candidates that target multiple pathways in tumor biology.
- EMD Serono: EMD Serono's commitment to advancing immuno-oncology is evident in its strategic partnerships and research initiatives focused on bispecific therapies.
- Merus: Merus has developed a unique platform for creating bispecific antibodies, with a focus on enhancing efficacy in cancer treatment through innovative mechanisms of action.
- Pieris Pharmaceuticals: Specializing in the development of protein therapeutics, Pieris is leveraging its proprietary technology to create bispecific antibodies aimed at various therapeutic areas.
- MacroGenics: This company has a robust pipeline of bispecific antibody candidates, with a focus on oncology and autoimmune diseases, capitalizing on the advantages of targeted therapy.
- Regeneron Pharmaceuticals: Known for its innovative monoclonal antibodies, Regeneron is exploring bispecific antibody formats to enhance therapeutic options in cancer treatment.
- Roche: Roche is a key player in the biopharmaceutical sector, with a strong focus on immunotherapy and bispecific antibody development for various indications.
- Adimab: This company utilizes its proprietary discovery platform to develop bispecific antibodies, emphasizing efficiency and speed in the drug development process.
Opportunities and Challenges
The bispecific antibody market holds a wealth of opportunities, particularly in untapped niches such as autoimmune diseases and personalized medicine. As healthcare continues to evolve, buyer personas are shifting, with patients seeking more tailored therapies that provide better outcomes with fewer side effects. Monetization avenues are also emerging through collaborations, licensing agreements, and strategic partnerships.
However, the market is not without its challenges. Regulatory hurdles pose significant barriers to the rapid development and approval of bispecific antibodies. Navigating the complex landscape of pharmaceutical research and meeting stringent regulatory requirements can be daunting for many companies. Additionally, supply chain gaps can hinder the timely production and distribution of new therapies. Practical solutions include investing in robust supply chain management systems and fostering transparent communication with regulatory bodies to streamline the approval process.
Technological Advancements
The bispecific antibody market is being transformed by cutting-edge technologies that enhance both the development and delivery of these therapies. Artificial intelligence is playing a pivotal role in drug discovery, allowing researchers to identify promising candidates and predict their efficacy more efficiently. Digital twins-virtual representations of physical entities-are being utilized to simulate patient responses, optimizing treatment plans.
The Internet of Things (IoT) is also making waves in the biotechnology sector, enabling real-time monitoring of clinical trial participants and enhancing data collection. Virtual reality is being explored as a tool for training and development, providing immersive environments for researchers and healthcare professionals. Additionally, blockchain technology is being increasingly adopted to ensure data integrity and security in clinical trials, fostering trust among stakeholders.
Research Methodology and Insights
At STATS N DATA, we employ a rigorous research methodology to deliver robust insights into the bispecific antibody market. Our approach combines both top-down and bottom-up analysis, ensuring a comprehensive understanding of market dynamics. We gather primary data through interviews with industry experts, key opinion leaders, and stakeholders, while secondary data is sourced from reputable industry reports, academic publications, and market databases.
By employing multi-layer triangulation, we validate our findings and provide actionable insights that empower decision-makers. This thorough approach positions STATS N DATA as a trusted authority in the bispecific antibody market, aiding executives and investors in navigating the complexities of this rapidly evolving sector.
The bispecific antibody market is experiencing unprecedented growth, driven by technological advancements and a shift towards personalized medicine. With a diverse range of applications and a competitive landscape of innovative players, the future of bispecific antibodies looks promising. As the market continues to evolve, staying informed about trends, opportunities, and challenges will be crucial for stakeholders in the biopharmaceutical sector. STATS N DATA remains committed to providing valuable insights and analysis, reinforcing its position as a leader in market research and thought leadership in the bispecific antibody domain.
For customization requests, please visit: https://www.statsndata.org/request-customization.php?id=162587
Access the full report analysis here: https://www.statsndata.org/report/bispecific-antibody-162587
Q: What are bispecific antibodies and how do they work?
A: Bispecific antibodies are engineered proteins that can simultaneously bind to two different antigens or epitopes. This unique mechanism allows them to bridge two distinct targets, which can be particularly useful in therapeutic applications. The structure of bispecific antibodies typically incorporates two different binding sites that can recognize two different proteins, often one being a tumor-associated antigen and the other being a T-cell receptor or another immune-related target. By bringing immune cells, such as T cells, into close proximity with cancer cells, bispecific antibodies can enhance the immune response against tumors. This approach can lead to more effective targeting of cancer cells while sparing normal cells, potentially reducing side effects compared to traditional treatments.
Q: Why are bispecific antibodies important in cancer treatment?
A: Bispecific antibodies are important in cancer treatment because they offer a novel approach to targeting tumors that may be resistant to conventional therapies. Traditional monoclonal antibodies typically target a single antigen, but many tumors can evade immune detection by downregulating or mutating their antigens. Bispecific antibodies can recognize multiple targets, making it more difficult for tumors to escape immune responses. They can also recruit and activate T cells directly at the tumor site, promoting a localized immune attack. This dual targeting mechanism enhances the potential for effective tumor destruction and improves the therapeutic index by minimizing damage to healthy tissue.
Q: How do bispecific antibodies differ from traditional monoclonal antibodies?
A: Bispecific antibodies differ from traditional monoclonal antibodies primarily in their ability to bind two different antigens instead of just one. Traditional monoclonal antibodies are designed to target a specific antigen on cancer cells, which can limit their effectiveness if the target is lost or altered. In contrast, bispecific antibodies can engage multiple targets, which allows them to overcome some of the limitations associated with traditional therapies. Additionally, bispecific antibodies can facilitate the recruitment of immune cells to the tumor microenvironment, enhancing the overall immune response. This multipronged approach can lead to improved efficacy in treating complex diseases like cancer.
Q: What are the potential benefits of using bispecific antibodies?
A: The potential benefits of using bispecific antibodies include increased specificity and potency in targeting cancer cells, improved immune cell activation, and a reduced risk of tumor escape mechanisms. By binding to two distinct targets, bispecific antibodies can effectively direct immune effector cells, such as T cells or NK cells, to the tumor site, thereby enhancing the immune response. They can also have a favorable safety profile, as their design can allow for selective targeting of tumor cells while sparing normal cells. Additionally, bispecific antibodies can provide new therapeutic options for patients with difficult-to-treat tumors, potentially leading to better clinical outcomes.
Q: How are bispecific antibodies developed and produced?
A: The development and production of bispecific antibodies involve several steps, starting with the identification of suitable targets. Researchers must select two distinct antigens that are relevant for the disease being targeted. Once targets are identified, various engineering techniques are employed to create a bispecific antibody. These methods may include hybridoma technology, genetic engineering, or the use of single-chain variable fragments. After the bispecific antibody is designed, it is expressed in host cells, often using mammalian cell lines to ensure proper folding and post-translational modifications. Subsequent purification and characterization steps ensure the antibody's quality and functionality before it enters preclinical and clinical testing.
Q: What diseases can bispecific antibodies treat?
A: Bispecific antibodies have shown promise in treating various diseases, particularly cancers. They are primarily being explored for hematologic malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma, as well as solid tumors like colorectal, breast, and lung cancers. Beyond oncology, bispecific antibodies are also being investigated for autoimmune diseases, infectious diseases, and other conditions where modulation of the immune response could be beneficial. The versatility of bispecific antibodies allows them to be tailored for specific therapeutic areas, making them a valuable tool in modern medicine.
Q: What are the current trends in bispecific antibody research?
A: Current trends in bispecific antibody research include the exploration of novel targets, optimization of bispecific formats, and combination therapies. Researchers are focusing on improving the design of bispecific antibodies to enhance their stability, efficacy, and safety profiles. There is also a growing interest in combining bispecific antibodies with other therapeutic modalities, such as checkpoint inhibitors or CAR T-cell therapies, to create synergistic effects. Additionally, advancements in biotechnology and engineering techniques are enabling the development of more sophisticated bispecific formats, such as dual-variable domain antibodies and modular bispecifics, which may improve performance in clinical settings.
Q: How do bispecific antibodies enhance immune response?
A: Bispecific antibodies enhance immune response by simultaneously engaging two different targets, which can include tumor antigens and immune effector cells. By binding to a tumor antigen, bispecific antibodies can mark cancer cells for destruction. Simultaneously, by binding to an immune cell receptor, such as CD3 on T cells, they can activate and direct these immune cells to the tumor site. This recruitment of immune cells leads to an amplified immune attack on the tumor, promoting cytotoxicity and potentially leading to tumor regression. The localized immune activation minimizes systemic side effects while maximizing therapeutic efficacy.
Q: What are the challenges in bispecific antibody development?
A: There are several challenges in bispecific antibody development, including engineering complexity, stability issues, and potential immunogenicity. Designing a bispecific antibody that retains the functional characteristics of both binding sites can be technically demanding. Stability during production and storage is crucial, as bispecific antibodies may have different stability profiles compared to traditional monoclonal antibodies. Additionally, the risk of immunogenic reactions can be a concern, as the introduction of a bispecific construct may elicit an immune response. Regulatory hurdles and the need for thorough clinical evaluation also present challenges in bringing bispecific antibodies to market.
Q: How do bispecific antibodies improve patient outcomes?
A: Bispecific antibodies improve patient outcomes by offering more effective and targeted treatment options, particularly for cancers that are resistant to conventional therapies. By simultaneously targeting multiple pathways or antigens, bispecific antibodies can circumvent tumor escape mechanisms, leading to improved response rates. Their ability to recruit and activate immune cells directly at the tumor site enhances the immune response, potentially leading to better disease control and longer-lasting remissions. In clinical trials, bispecific antibodies have shown promise in improving overall survival and quality of life for patients, making them a valuable addition to cancer treatment regimens.
Q: What role do bispecific antibodies play in immunotherapy?
A: Bispecific antibodies play a significant role in immunotherapy by providing a mechanism for harnessing the body's immune system to fight cancer. They facilitate the targeted recruitment of immune cells to tumor sites, enhancing the ability of the immune system to recognize and destroy cancer cells. This approach is particularly valuable in the context of tumors that may evade immune detection. Bispecific antibodies can be used in conjunction with other immunotherapeutic agents, such as checkpoint inhibitors or cancer vaccines, to create a more robust immune response. Their ability to engage multiple pathways makes them a key component in the evolving landscape of cancer immunotherapy.
Q: Are there any side effects associated with bispecific antibodies?
A: Yes, there are potential side effects associated with bispecific antibodies, similar to other immunotherapeutic agents. Side effects can range from mild to severe and may include infusion reactions, cytokine release syndrome (CRS), and neurological events. CRS occurs when a large number of immune cells are activated and release pro-inflammatory cytokines, leading to symptoms such as fever, fatigue, and hypotension. Other potential side effects may include changes in blood counts, liver function abnormalities, or autoimmune-like reactions. Continuous monitoring and management of these side effects are essential during treatment to optimize patient safety and comfort.
Q: What is the future outlook for bispecific antibodies in medicine?
A: The future outlook for bispecific antibodies in medicine is promising as ongoing research and technological advancements continue to enhance their design and application. As more bispecific antibodies move through clinical trials and gain regulatory approval, they are expected to become integral components of cancer treatment and other therapeutic areas. The ability to tailor bispecific antibodies to target specific patient populations or tumor characteristics aligns well with the principles of personalized medicine. Additionally, their role in combination therapies may further enhance their effectiveness and broaden their use in treating complex diseases. Overall, the bispecific antibody market is likely to expand significantly in the coming years.
Q: How are bispecific antibodies evaluated for efficacy?
A: Bispecific antibodies are evaluated for efficacy through a series of preclinical and clinical studies. Initially, preclinical studies involve testing the bispecific antibodies in vitro (in cell cultures) and in vivo (in animal models) to assess their binding affinity, biological activity, and therapeutic potential. Once promising results are obtained, clinical trials are conducted, typically in phases. Phase I trials focus on safety and dosage, while Phase II trials evaluate efficacy in a specific patient population. Phase III trials compare the bispecific antibody against standard treatments to assess overall effectiveness, progression-free survival, and other clinical endpoints. Regulatory agencies review data from these trials to determine whether the bispecific antibody can be approved for clinical use.
Q: What collaborations exist in bispecific antibody research?
A: Collaborations in bispecific antibody research often involve partnerships between biotechnology companies, pharmaceutical companies, academic institutions, and research organizations. These collaborations aim to leverage expertise in various areas such as antibody engineering, clinical development, and manufacturing. For example, large pharmaceutical companies may partner with smaller biotech firms that specialize in bispecific technology to develop novel therapeutics. Additionally, academic institutions often collaborate with industry partners to translate basic research into clinical applications. Such collaborations can accelerate the development of bispecific antibodies, enhance innovation, and bring new therapies to market more efficiently.
Q: How do bispecific antibodies fit into personalized medicine?
A: Bispecific antibodies fit into personalized medicine by enabling tailored treatments that address the unique characteristics of individual patients' tumors. By targeting specific antigens that are present on a patient's cancer cells and considering their immune profile, bispecific antibodies can be designed to optimize therapeutic efficacy for each patient. This personalized approach can lead to improved response rates, reduced side effects, and better overall outcomes. Moreover, the ability to combine bispecific antibodies with other targeted therapies allows for a more comprehensive treatment strategy that aligns with the principles of personalized medicine.
Q: What regulatory hurdles must bispecific antibodies overcome?
A: Bispecific antibodies must overcome several regulatory hurdles before they can be approved for clinical use. These hurdles include demonstrating safety and efficacy through rigorous clinical trials, ensuring consistency and quality in the manufacturing process, and addressing any potential immunogenicity concerns. Regulatory agencies, such as the FDA and EMA, require comprehensive data on the pharmacokinetics, pharmacodynamics, and toxicity profiles of bispecific antibodies. Additionally, the complexity of bispecific antibody formats may necessitate the development of specific guidelines for their evaluation. Gaining regulatory approval is a critical step that requires careful planning and execution during the development process.
Q: What is the market size for bispecific antibodies?
A: The market size for bispecific antibodies is rapidly growing, driven by increasing research and development activities, a rising prevalence of cancer, and the demand for innovative therapies. As of 2023, the global bispecific antibody market is estimated to be worth several billion dollars and is projected to continue expanding in the coming years. Factors contributing to this growth include the approval of new bispecific antibody therapies, advancements in manufacturing technologies, and increasing investments from pharmaceutical companies. The competitive landscape is also evolving, with numerous players entering the market, leading to a dynamic and innovative environment.
Q: How do bispecific antibodies impact cancer treatment strategies?
A: Bispecific antibodies impact cancer treatment strategies by offering new mechanisms of action that enhance the effectiveness of existing therapies. By targeting multiple pathways, bispecific antibodies can provide complementary effects to traditional treatments, such as chemotherapy and radiation. Their ability to engage the immune system directly at the tumor site leads to improved tumor recognition and destruction. This shift towards more targeted and personalized approaches in cancer treatment helps to optimize therapeutic outcomes and minimize adverse effects. Moreover, the versatility of bispecific antibodies allows for their integration into combination therapies, further enhancing treatment strategies and improving patient care.
Related Reports:
Intracranial Stenosis Stents Market
https://www.statsndata.org/report/intracranial-stenosis-stents-market-90135
Durian Market
https://www.statsndata.org/report/durian-market-26800
Remote Shutter Release Market
https://www.statsndata.org/report/remote-shutter-release-market-97495
Telecentric Lenses for Machine Vision Market
https://www.statsndata.org/report/telecentric-lenses-for-machine-vision-market-94708
Computer Aided Dispatch (CAD) Market
https://www.statsndata.org/report/computer-aided-dispatch-cad-market-132786"
John Jones
Sales & Marketing Head | Stats N Data
Email: sales@statsndata.org
Website: www.statsndata.org
STATS N DATA is a trusted provider of industry intelligence and market research, delivering actionable insights to businesses across diverse sectors. We specialize in helping organizations navigate complex markets with advanced analytics, detailed market segmentation, and strategic guidance. Our expertise spans industries including technology, healthcare, telecommunications, energy, food & beverages, and more.
Committed to accuracy and innovation, we provide tailored reports that empower clients to make informed decisions, identify emerging opportunities, and achieve sustainable growth. Our team of skilled analysts leverages cutting-edge methodologies to ensure every report addresses the unique challenges of our clients.
At STATS N DATA, we transform data into knowledge and insights into success. Partner with us to gain a competitive edge in today's fast-paced business environment.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bispecific Antibody Market with Insights from Immunomedics, Genmab, OncoMed pharma-healthcare, EMD Serono, Merus, Pieris, MacroGenics, Emergent BioSolutions here
News-ID: 4358276 • Views: …
More Releases from STATS N DATA
Bioresorbable Coronary Stents Market: Analysis Led by BIOTRONIK, Meril Lifescien …
Germany 21 January 2026 The bioresorbable coronary stents market is witnessing a significant transformation as it evolves to meet the demands of modern interventional cardiology. Bioresorbable stents, also known as biodegradable stents, are designed to provide temporary support to the coronary arteries while gradually dissolving in the body. This innovative approach aims to address the limitations of traditional metallic stents, particularly in the context of coronary artery disease.
You can access…
Biological Safety Cabinet Market with Insights from ESCO, Thermo Fisher Scientif …
The Biological Safety Cabinet (BSC) market serves as a critical pillar within the realm of laboratory safety equipment, protecting users, products, and the environment from biohazards. These cabinets are essential in various applications, including pharmaceutical research, clinical laboratories, and academic institutions. As the global demand for biosafety equipment surges, propelled by increased research activities and heightened awareness of biohazard risks, the BSC market is witnessing significant growth.
You can access a…
Future of Biohacking Market: Analysis Led by Fitbit, Apple, Synbiota, THE ODIN, …
Germany 21 January 2026 The biohacking market is rapidly emerging as a pivotal sector in the broader health and wellness industry, attracting attention from consumers, investors, and health enthusiasts alike. Defined as the practice of using science and technology to enhance the body and mind, biohacking encompasses a wide array of techniques aimed at achieving human optimization. From nootropics designed for brain enhancement to various health optimization strategies, biohacking serves…
Bioconjugation Market Innovations and Key Players: Genscript Biotech, Danaher, C …
Germany 21 January 2026 The bioconjugation market has witnessed remarkable growth in recent years, driven by advancements in bioconjugation technology and its diverse applications across various sectors. Bioconjugation, the process of covalently linking biomolecules to other molecules, has become instrumental in enhancing drug delivery systems, improving diagnostic accuracy, and facilitating innovative research methodologies. As the demand for bioconjugation applications continues to surge, the market is becoming increasingly competitive, prompting a…
More Releases for Bispecific
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Bispecific Drug Innovation - Creative Biolabs Concludes Its Journey at the 15th …
On September 5, Creative Biolabs successfully concluded its participation in the 15th Annual World Bispecific Summit.
New York, USA - September 10, 2024 - The summit brought together leading experts in the bispecific antibody [https://www.creative-biolabs.com/bsab/bispecific-antibody-bsab-development-service.htm] (BsAb) field from around the globe, offering attendees a rich platform to discuss cutting-edge developments and future directions.
Image: https://www.getnews.info/uploads/b7ea13d648fcb7917ba9b55571b2ba35.png
In recent years, this field has grown rapidly, becoming a focal point in biopharmaceutical research and development. A…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Global Bispecific Antibody Market Research Report Forecast 2017 to 2021Global Bi …
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Bispecific Antibody Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies.
The Global Bispecific Antibody Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Bispecific Antibody industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as…
Bispecific Antibodies Market - Global Industry Analysis 2024
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
